The American Society of Clinical Oncology (ASCO) invites you to submit your next article to JCO Precision Oncology (JCO PO).
JCO PO will offer a unique opportunity to have your precision oncology research make an impact on cancer care delivery and research via the unparalleled reach and reputation of ASCO. As a member benefit, nearly 40,000 of ASCO's members worldwide will have access to JCO PO. Articles published in JCO PO will also be promoted via ASCO member publications, communications, and social media, ensuring maximum exposure for your research.
JCO Precision Oncology will publish original research, reports, opinions, and reviews that will advance the science and practice of precision oncology and define genomics-driven clinical care of patients with cancer. Innovative and timely scientific and educational content will provide a deeper understanding of actionable cancer genomics, personalized translational and clinical oncology research, and recent treatment advances based on tumor molecular profiling. The scope of publications will include all types of clinical research (basket trials, exceptional response results, informatics, mechanism and evidence-based case reports and small series of educational value), and extensive expert driven commentary, editorials and reviews considering the challenges and value of targeted therapies based on genomic analyses. The first articles are scheduled to be published in late 2016 or early 2017.
For more information on submitting to JCO Precision Oncology, please sign up for our mailing list:
Dr. Ford is an Associate Professor of Medicine (Oncology), Pediatrics (Medical Genetics) and Genetics, and Director of the Stanford Cancer Genetics Clinic and the Cancer Genomics Program at the Stanford Cancer Institute. There, he performs next-generation tumor profiling to identify novel genetic targets for personalized targeted therapies. His research is dedicated to studying the genetic basis of breast and gastrointestinal cancer development, and the role of DNA repair in the treatment and prevention of cancer in families and populations.
With clinical interests in cancer genomics and the diagnosis and treatment of patients with a hereditary pre-disposition to cancer, Dr. Ford has published countless peer-reviewed articles focused on this area of research. He previously served as an editor for the journals Cancer Research, PLoS Genetics, and DNA Repair, and is on the Scientific Review Committee for the V Foundation for Cancer Research.
"Personalized treatment approaches allow us to glean valuable insights from each individual patient, creating a wealth of knowledge for us to build upon," said Dr. Ford. "This journal provides an important learning platform for the oncology community, and it is a privilege to lead the effort to grow and share this exciting research."
Shridar Ganesan, MD, PhD, Rutgers Cancer Institute of New Jersey, Westfield, NJ
Howard L. McLeod, PharmD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
Lincoln Nadauld, MD, PhD, Intermountain Healthcare, St. George, UT
Joshua David Schiffman, MD, University of Utah, Salt Lake City, UT
Dara Aisner, MD, PhD, University of Colorado, Aurora, CO
Himisha Beltran, MD, New York–Presbyterian Hospital, New York, NY
Daniel V.T. Catenacci, MD, University of Chicago, Chicago, IL
Ryan B. Corcoran, MD, PhD, Massachusetts General Hospital, Boston, MA
Adam Dicker, MD, PhD, Thomas Jefferson University Hospital, Philadelphia, PA
Heather Hampel, MS, LGC, The Ohio State University Comprehensive Cancer Center, Columbus, OH
Shivaani Kummar, MD, FACP, Stanford University, Palo Alto, CA
Patrick A. Ott, MD, PhD, Dana-Farber Cancer Institute, Boston, MA
Emanuel Petricoin, PhD, George Mason University, Manassas, VA
Kimryn Rathmell, MD, PhD, Vanderbilt University, Nashville, TN
Davendra Sohal, MD, MPH, Cleveland Clinic, Cleveland, OH